Partnership brings Parse Evercode single cell to Discovery Life Sciences’ biopharma, diagnostic, and academic client base
SEATTLE — November 17, 2026 — Parse Biosciences, the leading provider of scalable and accessible single-cell sequencing, and a QIAGEN company, today announced that Discovery Life Sciences (Discovery) has joined its Certified Service Provider (CSP) program. The partnership allows Discovery to offer Parse’s Evercode single-cell technology directly to its clients, expanding access to high-throughput single-cell analysis across industry markets.
Backed by deep expertise in cell biology, assay design, and sample preparation, Discovery helps biopharma and academic researchers to select the optimal single-cell strategy based on their scientific objectives. The company now offers Parse’s Evercode platform as part of its single-cell genomics services, providing researchers with a scalable workflow that uses combinational barcoding rather than specialized instrumentation to profile hundreds of thousands to millions of cells in a single run.
By combining large-scale, highly characterized biospecimen sourcing with integrated laboratory services, including single-cell genomics, Discovery enables researchers to move seamlessly from sample acquisition to data generation through a single trusted partner. This integrated approach brings together high-quality biospecimens, scientific expertise, and advanced single-cell capabilities to maximize biological insight and drive stronger research outcomes.
“Adding Parse’s Evercode platform gives our clients an effective way to scale single-cell studies without compromising on data quality. It’s a natural extension of the high standards we already hold for our cell biology and genomics services,” states Shawn Fahl, PhD, VP Cell Biology at Discovery Life Sciences.
“Discovery Life Sciences brings deep experience serving biopharma, diagnostic, and academic researchers, and now they can offer Evercode single-cell sequencing directly through this partnership. For the many labs already working with Discovery, that means faster access to single cell data without adding a new vendor to the mix,” states Charlie Roco, PhD, Chief Technology Officer at Parse.
About Discovery Life Sciences
Discovery Life Sciences is a global leader in biospecimens and specialty lab services, enabling the discovery and development of therapeutics and diagnostics that improve patient outcomes. Our extensive portfolio of normal and diseased human biospecimens, cellular starting materials, and preclinical ADME-tox products and services accelerates research with high-quality, highly characterized materials, complemented by expertise in cell biology. Our comprehensive suite of lab services, including molecular pathology, genomics, proteomics, and flow cytometry, delivers critical data and insights for biomarker discovery across the full spectrum of retrospective and prospective clinical trials, from assay development and validation through Phase 3 and post-approval pathologist training. With a vision to be the most trusted partner in life science research and clinical development, Discovery Life Sciences is committed to advancing scientific research and transforming lives.
パース・バイオサイエンシズについて
Parse Biosciences, a QIAGEN company, is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system.
Contact:
Kaitie Kramer
| 858.504.0455